De-regulated FGF receptors as therapeutic targets in cancer

Pharmacology and Therapeutics

Volumn 125, Issue 1, 2010, Pages 105-117

  Knights, Victoria ^a   Cook, Simon J ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Cancer; FGFR; Kinase inhibitors; Signal transduction; Therapeutics

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ALKYLATING AGENT; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BCG VACCINE; BORTEZOMIB; CEDIRANIB; CETUXIMAB; DOVITINIB; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR BLOCKING AGENT; GEFITINIB; IMATINIB; KI 23057; LAPATINIB; LENALIDOMIDE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SMALL MOLECULE FIBROBLAST GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR; SORAFENIB; STEROID; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER GENETICS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOLOGY; DIARRHEA; DRUG HALF LIFE; DRUG TARGETING; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; UROTHELIAL CARCINOMA; VOMITING;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 72049092008     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.10.001     Document Type: Review

References (139)

1. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 6 (2003) 831-843
2. Bakkar A.A., Wallerand H., Radvanyi F., Lahaye J.B., Pissard S., Lecerf L., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63 23 (2003) 8108-8112
3. Balmanno K., and Cook S.J. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Diff 16 3 (2009) 368-377
4. Balmanno K., Chell S.D., Gillings A.S., Hayat S., and Cook S.J. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 125 10 (2009) 2332-2341
5. Basilico C., and Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 59 (1992) 115-165
6. Beenken A., and Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8 3 (2009) 235-253
7. Bernard-Pierrot I., Brams A., Dunois-Lardé C., Caillault A., Diez de Medina S.G., Cappellen D., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27 4 (2006) 740-747
8. Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de Medina S., Van Rhijn B., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158 6 (2001) 1955-1959
9. Brondello J.M., Pouysségur J., and McKenzie F.R. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286 5449 (1999) 2514-2517
10. Brummer T., Naegele H., Reth M., and Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 22 55 (2003) 8823-8834
11. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 6 (1999) 857-868
12. Byron S.A., Gartside M.G., Wellens C.L., Mallon M.A., Keenan J.B., Powell M.A., et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68 17 (2008) 6902-6907
13. Cabrita M.A., and Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 11 1 (2008) 53-62
14. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23 1 (1999) 18-20
15. Chase A., Grand F.H., and Cross N.C. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110 10 (2007) 3729-3734
16. Chen G.J., and Forough R. Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs. Recent Pat Cardiovasc Drug Discov 1 2 (2006) 211-224
17. Chen J., Williams I.R., Lee B.H., Duclos N., Huntly B.J., Donoghue D.J., et al. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood 106 1 (2005) 328-337
18. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97 3 (2001) 729-736
19. Cross M.J., Lu L., Magnusson P., Nyqvist D., Holmqvist K., Welsh M., et al. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells. Mol Biol Cell 13 8 (2002) 2881-2893
20. Dancey J., and Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2 4 (2003) 296-313
21. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 2 (1997) 231-241
22. Dawson M.A., Opat S.S., Taouk Y., Donovan M., Zammit M., Monaghan K., et al. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res 15 2 (2009) 714-722
23. Demiroglu A., Steer E.J., Heath C., Taylor K., Bentley M., Allen S.L., et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 98 13 (2001) 3778-3783
24. Ding W., Bellusci S., Shi W., and Warburton D. Functional analysis of the human Sprouty2 gene promoter. Gene 322 (2003) 175-185
25. Downward. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 1 (2003) 11-22
26. Dring A.M., Davies F.E., Fenton J.A., Roddam P.L., Scott K., Gonzalez D., et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 10 17 (2004) 5692-5701
27. Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D., Ballinger D.G., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 7148 (2007) 1087-1093
28. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 5827 (2007) 1039-1043
29. Eswarakumar V.P., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 2 (2005) 139-149
30. Ezzat S., Huang P., Dackiw A., and Asa S. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11 3 (2005) 1336-1341
31. Fabbro D., and Manley P.W. Su-6668. SUGEN. Curr Opin Investig Drugs 2 8 (2001) 1142-1148
32. Fenton J.A.L., Pratt G., Rawstron A.C., and Morgan G.J. Isotype class switching and the pathogenesis of multiple myeloma. Hematol Oncol 20 (2002) 75-85
33. Furdui C.M., Lew E.D., Schlessinger J., and Anderson K.S. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 21 5 (2006) 711-717
34. Gillings A.S., Balmanno K., Wiggins C.M., Johnson M., and Cook S.J. BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 276 21 (2009) 6050-6062
35. Grand E.K., Chase A.J., Heath C., Rahemtulla A., and Cross N.C. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18 5 (2004) 962-966
36. Grand E.K., Grand F.H., Chase A.J., Ross F.M., Corcoran M.M., Oscier D.G., et al. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 40 1 (2004) 78-83
37. Häcker U., Nybakken K., and Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 6 7 (2005) 530-541
38. Hacohen N., Kramer S., Sutherland D., Hiromi Y., and Krasnow M.A. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92 2 (1998) 253-263
39. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22 6 (2008) 1301-1309
40. Hara T., Ooi A., Kobayashi M., Mai M., Yanagihara K., and Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 78 9 (1998) 1143-1153
41. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
42. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13 2 (2000) 193-207
43. Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., and Donoghue D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19 29 (2000) 3309-3320
44. Hattori Y., Odagiri H., Nakatani H., Miyagawa K., Naito K., Sakamoto H., et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci U S A 87 15 (1990) 5983-5987
45. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68 12 (2008) 4774-4782
46. Huynh H., Ngo V.C., Fargnoli J., Ayers M., Soo K.C., Koong H.N., et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14 19 (2008) 6146-6153
47. Imai K., and Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6 9 (2006) 714-727
48. Jagannath S. Pathophysiological underpinnings of multiple myeloma progression. JMCP 14 7 (2008) S7-S11
49. Jang J.H., Shin K.H., and Park J.G. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61 9 (2001) 3541-3543
50. Jeffers M., LaRochelle W.J., and Lichenstein H.S. Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets 6 4 (2002) 469-482
51. Johnson L.N., Lowe E.D., Noble M.E., and Owen D.J. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett 430 1-2 (1998) 1-11
52. Keats J.J., Reiman T., Belch A.R., and Pilarski L.M. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 47 11 (2006) 2289-2300
53. Kimura T., Suzuki H., Ohashi T., Asano K., Kiyota H., and Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92 10 (2001) 2555-2561
54. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 3 (2006) 361-373
55. Kokel M., Borland C.Z., DeLong L., Horvitz H.R., and Stern M.J. clr-1 encodes a receptor tyrosine phosphatase that negatively regulates an FGF receptor signaling pathway in Caenorhabditis elegans. Genes Dev 12 10 (1998) 1425-1437
56. Kono S.A., Marshall M.E., Ware K.E., and Heasley L.E. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 278 4-5 (2009) 14087-14091
57. Kovalenko D., Yang X., Nadeau R.J., Harkins L.K., and Friesel R. Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J Biol Chem 278 16 (2003) 14087-14091
58. Koziczak M., Holbro T., and Hynes N.E. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23 20 (2004) 3501-3508
59. Kumar R., Knick V.B., Rudolph S.K., Johnson J.H., Crosby R.M., Crouthamel M.C., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6 7 (2007) 2012-2021
60. Kunii K., Davis L., Gorenstein J., Hatch H., Yashiro M., Di Bacco A., et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 68 7 (2008) 2340-2348
61. Kuniyasu H., Yasui W., Kitadai Y., Yokozaki H., Ito H., and Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189 1 (1992) 227-232
62. Kwabi-Addo B., Ropiquet F., Giri D., and Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 46 2 (2001) 163-172
63. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 6 (2008) 2962-2972
64. Laird A.D., Vajkoczy P., Shawver L.K., Thurnher A., Liang C., Mohammadi M., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60 15 (2000) 4152-4160
65. Langlois W.J., Sasaoka T., Saltiel A.R., and Olefsky J.M. Negative feedback regulation and desensitization of insulin- and epidermal growth factor-stimulated p21ras activation. J Biol Chem 270 43 (1995) 25320-25323
66. Lao D.H., Chandramouli S., Yusoff P., Fong C.W., Saw T.Y., Tai L.P., et al. A Src homology 3-binding sequence on the C terminus of Sprouty2 is necessary for inhibition of the Ras/ERK pathway downstream of fibroblast growth factor receptor stimulation. J Biol Chem 281 40 (2006) 29993-30000
67. Lew E.D., Furdui C.M., Anderson K.S., and Schlessinger J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal 2 58 (2009) ra6
68. Ley R., Balmanno K., Hadfield K., Weston C., and Cook S.J. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278 21 (2003) 18811-18816
69. Li X., Brunton V.G., Burgar H.R., Wheldon L.M., and Heath J.K. FRS2-dependent SRC activation is required for fibroblast growth factor receptor-induced phosphorylation of Sprouty and suppression of ERK activity. J Cell Sci 117 25 (2004) 6007-6017
70. Li C., Chen L., Iwata T., Kitagawa M., Fu X.Y., and Deng C.X. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet 8 1 (1999) 35-44
71. Li Z., Zhu Y.X., Plowright E.E., Bergsagel P.L., Chesi M., Patterson B., et al. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 97 8 (2001) 2413-2419
72. Lorenzi M.V., Castagnino P., Chen Q., Chedid M., and Miki T. Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations. Oncogene 15 7 (1997) 817-826
73. Mandl M., Slack D.N., and Keyse S.M. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol 25 5 (2005) 1830-1845
74. Marek L., Ware K.E., Fritzsche A., Hercule P., Helton W.R., Smith J.E., et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75 1 (2009) 196-207
75. Martínez-Torrecuadrada J., Cifuentes G., López-Serra P., Saenz P., Martínez A., and Casal J.I. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11 17 (2005) 6280-6290
76. Mason J.M., Morrison D.J., Bassit B., Dimri M., Band H., Licht J.D., et al. Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. Mol Biol Cell 15 5 (2004) 2176-2188
77. Mason J.M., Morrison D.J., Basson M.A., and Licht J.D. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol 16 1 (2006) 45-54
78. McDermott L.A., Simcox M., Higgins B., Nevins T., Kolinsky K., Smith M., et al. RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation. Bioorg Med Chem 13 16 (2005) 4835-4841
79. McLeskey S.W., Zhang L., El-Ashry D., Trock B.J., Lopez C.A., Kharbanda S., et al. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182, 780 and two aromatase inhibitors. Clin Cancer Res 4 3 (1998) 697-711
80. Meloche S., and Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26 22 (2007) 3227-3239
81. Moffa A.B., Tannheimer S.L., and Ethier S.P. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2 11 (2004) 643-652
82. Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W., et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol 11 10 (1991) 5068-5078
83. Mor O., Ranzani G.N., Ravia Y., Rotman G., Gutman M., Manor A., et al. DNA amplification in human gastric carcinomas. Cancer Genet Cytogenet 65 2 (1993) 111-114
84. Nakamura K., Yashiro M., Matsuoka T., Tendo M., Shimizu T., Miwa A., et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131 5 (2006) 1530-1541
85. Olsen S.K., Garbi M., Zampieri N., Eliseenkova A.V., Ornitz D.M., Goldfarb M., et al. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem 278 36 (2003) 34226-34236
86. Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A., et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A 101 4 (2004) 935-940
87. Ong S.H., Guy G.R., Hadari Y.R., Laks S., Gotoh N., Schlessinger J., et al. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol 20 3 (2000) 979-989
88. Ong S.H., Hadari Y.R., Gotoh N., Guy G.R., Schlessinger J., and Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A 98 11 (2001) 6074-6079
89. Onose H., Emoto N., Sugihara H., Shimizu K., and Wakabayashi I. Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. Eur J Endocrinol 140 2 (1999) 169-173
90. Ornitz D.M., and Itoh N. Fibroblast growth factors. Genome Biol 2 3 (2001) REVIEWS3005
91. Ozaki K., Miyazaki S., Tanimura S., and Kohno M. Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. J Cell Sci 118 24 (2005) 5861-5871
92. Powers C.J., McLeskey S.W., and Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7 3 (2000) 165-197
93. Plotnikov A.N., Schlessinger J., Hubbard S.R., and Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 98 5 (1999) 641-650
94. Plowright E.E., Li Z., Bergsagel P.L., Chesi M., Barber D.L., Branch D.R., et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 95 3 (2000) 992-998
95. Preger E., Ziv I., Shabtay A., Sher I., Tsang M., Dawid I.B., et al. Alternative splicing generates an isoform of the human Sef gene with altered subcellular localization and specificity. Proc Natl Acad Sci U S A 101 5 (2004) 1229-1234
96. Qing J., Du X., Chen Y., Chan P., Li H., Wu P., et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 119 5 (2009) 1216-1229
97. Ray M.E., Yang Z.Q., Albertson D., Kleer C.G., Washburn J.G., Macoska J.A., et al. Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res 64 1 (2004) 40-47
98. Reichert J.M., Rosensweig C.J., Faden L.B., and Dewitz M.C. Monoclonal antibody successes in the clinic. Nat Biotechnol 23 9 (2005) 1073-1078
99. Reis-Filho J.S., Simpson P.T., Turner N.C., Lambros M.B., Jones C., Mackay A., et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12 22 (2006) 6652-6662
100. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70 (2001) 281-312
101. Roumiantsev S., Krause D.S., Neumann C.A., Dimitri C.A., Asiedu F., Cross N.C., et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 5 3 (2004) 287-298
102. Rubin C., Zwang Y., Vaisman N., Ron D., and Yarden Y. Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. J Biol Chem 280 10 (2005) 9735-9744
103. Sandilands E., Akbarzadeh S., Vecchione A., McEwan D.G., Frame M.C., and Heath J.K. Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors. EMBO Rep 8 12 (2007) 1162-1169
104. Sarker D., Molife R., Evans T.R., Hardie M., Marriott C., Butzberger-Zimmerli P., et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14 7 (2008) 2075-2081
105. Sellers A.H. The staging of breast cancer, trial of the TNM method. Can J Surg 4 (1960) 116-117
106. Shaul Y.D., and Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773 8 (2007) 1213-1226
107. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
108. Sleeman M., Fraser J., McDonald M., Yuan S., White D., Grandison P., et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 271 2 (2001) 171-182
109. Smith T.G., Karlsson M., Lunn J.S., Eblaghie M.C., Keenan I.D., Farrell E.R., et al. Negative feedback predominates over cross-regulation to control ERK MAPK activity in response to FGF signalling in embryos. FEBS Lett 580 17 (2006) 4242-4245
110. Soler G., Nusbaum S., Varet B., Macintyre E.A., Vekemans M., Romana S.P., et al. LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome. Leukemia 23 7 (2009) 1359-1361
111. Streit S., Bange J., Fichtner A., Ihrler S., Issing W., and Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111 2 (2004) 213-217
112. Suhardja A., and Hoffman H. Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech 60 1 (2003) 70-75
113. Takeda M., Arao T., Yokote H., Komatsu T., Yanagihara K., Sasaki H., et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 13 10 (2007) 3051-3057
114. Tannheimer S.L., Rehemtulla A., and Ethier S.P. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2 4 (2000) 311-320
115. Thomson S., Petti F., Sujka-Kwok I., Epstein D., and Haley J.D. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25 8 (2008) 843-854
116. Tomlinson D.C., Baldo O., Harnden P., and Knowles M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213 1 (2007) 91-98
117. Tomlinson D.C., Hurst C.D., and Knowles M.A. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 26 40 (2007) 5889-5899
118. Tomlinson D.C., L'Hôte C.G., Kennedy W., Pitt E., and Knowles M.A. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 65 22 (2005) 10441-10449
119. Tomlinson D.C., Lamont F.R., Shnyder S.D., and Knowles M.A. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 69 11 (2009) 4613-4620
120. Trudel S., Ely S., Farooqi Y., Affer M., Robbiani D.F., Chesi M., et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103 9 (2004) 3521-3528
121. Trudel S., Li Z.H., Wei E., Wiesmann M., Chang H., Chen C., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105 7 (2005) 2941-2948
122. Trudel S., Stewart A.K., Rom E., Wei E., Li Z.H., Kotzer S., et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107 10 (2006) 4039-4046
123. Tsang M., Friesel R., Kudoh T., and Dawid I.B. Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol 4 2 (2002) 165-169
124. Tsujimoto H., Sugihara H., Hagiwara A., and Hattori T. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 431 6 (1997) 383-389
125. Weinstein I.B., and Joe A.K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3 8 (2006) 448-457
126. Welm B.E., Freeman K.W., Chen M., Contreras A., Spencer D.M., and Rosen J.M. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 157 4 (2002) 703-714
127. Wong A., Lamothe B., Lee A., Schlessinger J., and Lax I. FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci U S A 99 10 (2002) 6684-6689
128. Xian W., Schwertfeger K.L., Vargo-Gogola T., and Rosen J.M. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 171 4 (2005) 663-673
129. Xian W., Pappas L., Pandya D., Selfors L.M., Derksen P.W., de Bruin M., et al. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res 69 (2009) 2244-2251
130. Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 18 1 (1998) 84-87
131. Yagasaki F., Wakao D., Yokoyama Y., Uchida Y., Murohashi I., Kayano H., et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res 61 23 (2001) 8371-8374
132. Yamaguchi F., Saya H., Bruner J.M., and Morrison R.S. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci U S A 91 2 (1994) 484-488
133. Yashiro M., Nishioka N., and Hirakawa K. K-ras mutation influences macroscopic features of gastric carcinoma. J Surg Res 124 1 (2005) 74-78
134. Yokota J., Yamamoto T., Miyajima N., Toyoshima K., Nomura N., Sakamoto H., et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2 3 (1988) 283-287
135. Yoshida T., Sakamoto H., and Terada M. Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 4 1 (1993) 33-40
136. Yusoff P., Lao D.H., Ong S.H., Wong E.S., Lim J., Lo T.L., et al. Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J Biol Chem 277 5 (2002) 3195-3201
137. Zhang J., Yang P.L., and Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9 1 (2009) 28-39
138. http://www.cancerhelp.org.uk.
139. http://www.valstarsolution.com.